Pentosan polysulphate prolongs survival in CJD, study indicatesBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7560.166-d (Published 20 July 2006) Cite this as: BMJ 2006;333:166
- Owen Dyer
An experimental treatment for Creutzfeldt-Jakob disease (CJD) may prolong life but does not seem to halt progressive deterioration of the brain, a study of seven British patients who took the drug has found.
Pentosan polysulphate, widely prescribed in pill form around the world for urological conditions, is infused directly into the brain of patients with CJD.
Ian Bone, a Glasgow neurologist, did the study on behalf of the Medical Research Council. Of the seven patients, three had variant CJD (vCJD, contracted from bovine spongiform encephalopathy); two had iatrogenic prion disease from growth hormone; and two had the hereditary form of CJD. All were …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial